key: cord-0278856-jcuygqzh
authors: Chevillard, C; Amen, A; Besson, S; Hannani, D; Bally, I; Dettling, V; Gout, E; Moreau, CJ; Buisson, M; Gallet, S; Fenel, D; Vassal-Stermann, E; Schoehn, G; Poignard, P; Dagher, MC; Fender, P
title: Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform
date: 2021-09-13
journal: bioRxiv
DOI: 10.1101/2021.09.13.460076
sha: d6617031343aa510e7cac9f73d231c3efd42927a
doc_id: 278856
cord_uid: jcuygqzh

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has shown that vaccine preparedness is critical to anticipate a fast response to emergent pathogens with high infectivity. To rapidly reach herd immunity, an affordable, easy to store and versatile vaccine platform is thus desirable. We previously designed a non-infectious adenovirus-inspired nanoparticle (ADDomer), and in the present work, we efficiently decorated this original vaccine platform with glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryo-Electron Microscopy structure revealed that up to 60 copies of this antigenic domain were bound on a single ADDomer particle with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated particles showed as early as the first immunization a significant anti-coronavirus humoral response, which was boosted after a second immunization. Neutralization assays with spike pseudo-typed-virus demonstrated the elicitation of strong neutralization titers. Remarkably, the existence of pre-existing immunity against adenoviral-derived particles enhanced the humoral response against SARS-CoV-2. This plug and play vaccine platform revisits the way of using adenovirus to combat emergent pathogens while potentially taking advantage of the adenovirus pre-immunity.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan, China in 2019 causes severe pneumonia with 4 574 089 deaths as of September 8, 2021 (https://covid19.who.int/) and enormous socio-economic consequences 1 . SARS-CoV-2 is an enveloped positive strand RNA virus belonging to the beta-coronavirus genus from the coronaviridae family. On its membrane surface, it exposes the membrane heterotrimeric glycoprotein protein S, known as the Spike. The ectodomain of the S protein is divided into S1 and S2 domains. Both SARS-CoV-2 and SARS-CoV Spike proteins bind to a host Angiotensin-Converting Enzyme 2 (ACE2), which serves as an entry receptor. A subdomain of the S1 domain, named receptor binding domain (RBD) 2,3 , is the contact interface between the virus and the ACE2 receptors. Several neutralizing antibodies (NAbs) 4 

shown strong inhibition of cell infection by SARS-CoV-2 by competing with the RBD-ACE2

interaction.

The cryo-EM structure of the receptor/spike complex enabled to define precisely the key residues involved in the contacts and showed that their mutations altered binding affinity 2,3,6,7 .

Due to its surface-exposed location and critical role in entry, the S protein is a main target of NAbs upon infection and therefore a good candidate for vaccine design. Thus, most vaccines currently licensed for humans use this protein as an antigen. Vaccine platforms are essentially based on the use of recombinant adenoviral vectors or mRNA. Adenovirus is an attractive nonreplicative vector because of its ease of production and storage and was used in several of the currently authorized COVID vaccines 8 . However, pre-existing immunity in the human population is a potential concern to the effectiveness of such delivery vehicles resulting in the use of a non-human derived adenoviral vector or alternating use of several human serotypes such as HAdV-5 and HAdV-26 8 .

Beside the whole S protein, numerous studies have shown that the RBD comprises multiple distinct antigenic sites and is a prime target for neutralizing antibodies in COVID-19 convalescent patients [9] [10] [11] [12] . Moreover, these NAbs have been shown to confer protection against SARS-CoV-2 challenge in animal models of COVID-19, as well as to prevent COVID-19 in human, thus confirming the interest of using RBD as a vaccine immunogen 13, 14, 15 .

We have previously reported that a non-infectious particle derived from human Adenovirus of type 3 consisting of 60 identical penton base monomers could be modified to display epitopes of interest including those from emerging viruses as its surface [16] [17] [18] . In this vaccine platform named ADDomer, exposed loops of the penton base protein were engineered to allow insertion of foreign peptides such as a linear neutralizing epitope from Chikungunya virus. However, insertion of structurally complex antigens was not permitted by this first platform. To overcome this limitation while keeping the immunological advantages of ADDomer, we describe here a novel adenovirus-inspired vaccine platform offering a unique highly versatile display of large and structurally complex antigens with post-translational modifications. To allow the versatile insertion of large antigens, the Spy Tag/Spy Catcher system [19] [20] [21] [22] was combined to the ADDomer technology. In this system derived from Streptococcus pyogenes an Aspartate residue from the 13 amino-acid SpyTag peptide (ST) can spontaneously create a covalent bond with a Lysine residue encompassed in the complementary SpyCatcher module (SC). We genetically inserted the sequence coding the ST peptide into the 'variable loop' of the ADDomer that was previously used for small antigen insertion. On the other hand, the RBD antigen from SARS-CoV-2 virus was fused to SC, in order to make a novel and original ADDomer-based COVID-19 vaccine. Here, we report that the newly designed platform can successfully be decorated with SARS-CoV-2 RBD and is highly immunogenic in mice, eliciting high neutralizing Ab titers.

ADDomer is a non-infectious 30 nm nanoparticle, formed from 12 bricks of the homopentameric penton base from the human adenovirus type 3. The ST sequence was inserted in the ADDomer gene in a region coding for the exposed flexible loop called the variable loop ( Figure 1a ). Due to the spontaneous homo-oligomerization of twelve pentameric penton base, sixty copies of ST are exposed on the surface of the ADDomer-ST (ADD-ST) particle. To assess whether the newly inserted ST sequence was accessible and functional on ADD-ST, incubation with different ratio of SC was performed. SDS-PAGE profile clearly showed that the incremental SC/ADD-ST ratio is correlated with the apparition of a band of higher molecular weight and the decrease of the intensity of bands related to unlinked moieties.

Importantly, there was no remaining signal for undecorated ADD-ST after SC addition at the highest ratio thus reflecting the full decoration of the nanoparticle (Figure 1b) . This result suggests an efficient and concentration-dependent formation of the ADD-ST/SC complex.

Mass spectroscopy analysis confirmed that the ADD-ST doublet shifted by 13,3kDa ( Figure   1c ), which corresponds to the molecular weight (MW) of SC. The two peaks observed in mass spectroscopy is due to a second initiation codon in ADD-ST (starting at Methionine 25) and SC can bind to each form indifferently as shown by a similar shift of their MW corresponding to the addition of SC. Negative staining electron microscopy imaging performed on ADD-ST alone and ADD-ST fully decorated by SC showed that the integrity of the particle was not affected by the presence of SC and the grainy appearance of ADD-ST/SC likely reflects the presence of SC at the particle surface ( Figure 1d ). Altogether, these data show that SC crosslinking to ADD-ST is operational and can result in saturated decoration of the nanoparticle.

-

In order to visualize the SC arrangement around the ADDomer particle, a structural study by cryo-electron microscopy was used. Fully decorated ADD-ST/SC particles were imaged on a Glacios electron microscope (Figure 2a ). Image analysis was performed and the obtained 3D structure was compared to the structure of an undecorated ADDomer particle (EMD-0198).

An extra-density corresponding to SC bound to the ADDomer 'variable loop' was clearly visible in ADD-ST/SC both in the density slice of the 3D map ( Figure 2b ) and in the isosurface representation of the structure (Figure 2c , purple density). The resolution of the ADDomer particle is around 2.8 Å, allowing to clearly see the aminopeptidic chain. However, the ST/SC part is not rigidly attached to the ADDomer, which explain why the corresponding density is fuzzy, and the structure not better defined. The ADDomers have 2, 3 and 5 axis of symmetry, (the latter two being shown in Figure 2c ), which is a characteristic of a dodecahedron meaning that SC are distributed accordingly. Interestingly, along the 3-fold axis SC are ~ 4.7 nm apart which is close to the Receptor Binding Domain (RBD) in the trimeric spike protein of SARS-CoV-2 (~ 4.1 nm), suggesting that the decorated particles would closely mimic the natural trimeric arrangement of RBDs (Figure 2d ). Both the multivalency of SC displayed by the particle and the arrangements they have around the different symmetry axis could be an asset for vaccination purpose if an antigen is fused to this module.

-Secreted RBD fused to SC is glycosylated and can be displayed at different ratios on the ADD-ST particle

To take advantage of the spontaneous and covalent linking of SC to ADD-ST, we reasoned that SC could be used as a versatile carrier to easily and efficiently fuse epitopes, like in this SARS-CoV-2 vaccine development (Figure 3a) , and in broader perspectives to diverse soluble proteins of interest. In the present study, the SARS-CoV-2 RBD was fused to the N-terminus of the SC present at the surface of the HeLa cells ( Figure 4b ). Finally, a competition experiment between a pseudo-typed virus harboring the SARS-CoV-2 spike and either RBD-SC or ADD-RBD was performed. Negative control was made with undecorated ADD-ST alone. As expected, both RBD-SC alone and ADD-RBD were able to compete with the pseudo-typed virus with a slightly higher efficiency for the RBD-decorated particle (Fig. 4c) . Altogether, these experiments showed that RBD-SC is properly folded and can bind the ACE2 receptor at the molecular and cellular scales when applied alone (RBD-SC) or linked to the ADDomer particles (ADD-RBD).

-

Multivalent exposition of RBD antigens at the surface of the particle is likely to result in a better activation of the humoral system than RBD alone. However, one cannot exclude that ADDomer itself could also play an indirect role in the anti-SARS-CoV-2 response, especially in a population with preexisting adenovirus immunity. To address these two points, four groups of ten mice were designed ( Figure 5a ). The two first control groups were injected with RBD-SC alone in the group 1 or with the same amount of unlinked RBD-SC plus naked-ADDomer (i.e.

not displaying the antigen) in the group 2. The two other groups (groups 3 and 4) were vaccinated with ADD-RBD (i.e. RBD displayed at the particle surface) but the group 4 was pre-immunized with naked-ADDomer two weeks before the injection of ADD-RBD, to investigate the role of adenovirus pre-immunity ( Figure 5b ). The presence of anti-adenovirus antibodies in group 4 was checked one day before the first immunization with ADD-RBD by ELISA using anti-ADDomer antibodies. The results (Supplementary Figure 1) show that all mice of this group were preimmunized against naked-ADDomer. Then, the immune response against RBD was monitored by ELISA at day 13 (post-1 st immunization) and day 27 and 41

(post-2 nd immunization). The RBD-decorated particles induced a significant anti-SARS-CoV-2 response after the first immunization (day 13, figure 5c), whereas no response was detectable in controls of group 1 (RBD-SC alone) or group 2 (ADDomer with not displayed SC-RBD).

Interestingly, adenovirus pre-immunity enhanced significantly the anti-RBD response.

-

Two weeks after the second immunization (day 27), the anti-RBD response was clearly boosted for groups 3 and 4 that were injected with ADD-RBD, whereas the control groups 1 and 2 showed more heterogeneous responses (Figure 6a ). This observation definitely confirms that our vaccine platform displaying multivalent RBD antigens yields a rapid and efficient humoral response. The ADDomer technology applied to RBD antigen also demonstrated a long lasting immunogenic effect with anti-SARS-CoV-2 RBD antibodies remaining at the highest level at day 41 ( Figure 6b) . The difference between mice pre-immunized by adenovirus (group 4) or not (group 3) was less pronounced than after the first immunization, both groups reaching high and comparable levels. Altogether, these results showed that the second immunization enabled a high and long-lasting antibody response against the SARS-CoV-2 RBD using the ADDomer platform and that adenovirus pre-immunity is beneficial in particular to the initial responses ( Figure 6c ).

-

Since the RBD is critical for binding to the SARS-CoV-2 receptor ACE2, antibodies elicited through immunization with the RBD (RBD-SC or ADDomer-RBD) can hinder the interaction between the Spike proteins and ACE2, blocking viral entry. The ability to neutralize the virus depends on the affinity of the antibodies for the RBD domain, as well as on the epitope recognized. To assess the potency and efficacy of the antibodies induced in the four immunized groups of mice, the neutralization potency of sera (day 41) from vaccinated mice were assessed using SARS-CoV-2 spike (Wuhan strain) pseudo-typed virus and ACE2-expressing HeLa cells.

Only a partial and heterogeneous neutralization was obtained from groups 1 and 2 sera in which RBD-SC was not displayed on ADDomer even after two immunizations (Figure 7a , upper panels). Of note, sera from mice immunized with RBD-decorated ADDomer (groups 3 and 4)

showed a better neutralization titer even after a single injection (Supplementary Figure 2) . After the second immunization, strong virus neutralization was observed in all mice from groups 3 and 4 (Figure7a, lower panels). Neutralization titer calculation (ND50) clearly showed that mice vaccinated with RBD-decorated ADDomer had significantly higher neutralizing antibody titers than mice injected with the same amount of antigen but not displayed on the platform ( Figure   7b ). Moreover, in accordance with the ELISA results (Figure 5c ), the adenovirus pre-existing immunity (group 4) slightly increased the neutralization titer compared to the naïve group (group 3), which emphasizes that this pre-existing adenovirus immunity appears beneficial for our novel vaccine platform (Figure 7b ).

In this study, we designed a novel and highly versatile vaccine platform amenable to large antigens by adapting the SpyTag/SpyCatcher technology to ADDomer, an adenovirus-inspired virus-like particle (VLP) 18, 19 . This technology has already been described for designing VLPderived vaccine, however in these approaches SC was the moiety grafted to the VLPs while the antigens were fused to the Spy Tag 20,24 . In our novel vaccine technology, we used the opposite configuration with SpyTag insertion in an internal loop of ADDomer, which minimized the risk of steric hindrance and functional impact on the spontaneous oligomerization of ADDomers.

Insertion of ST in a surface-exposed loop of ADDomer did not impair the spontaneous assembly of twelve pentameric bricks (Figure 1d ), thus creating a universal generic platform for multivalent antigen display. Experiments of saturating cross-linking with SC alone suggested that a full decoration (i.e. 60 copies) of the particle can be achieved (Figure 1b) . The COVID pandemic led us to first evaluate our newly designed platform as an anti-SARS-CoV-2 vaccine, using the RBD as the antigen to be displayed through fusion to the SC Nterminus. It is worth noting that in the 3-fold axis of ADDomer, the SC adopts a pseudo-trimeric arrangement, which on the RBD decorated VLP closely mimics the tridimensional configuration of this domain in the SARS-CoV-2 spike glycoprotein (Figure 2d ). The distance between SC in such configuration is 4,7 nm, which is in the same range as that between RBDs in the trimeric Spike protein (4,1 nm). Expressing soluble RBD fused to SC in insect cells resulted in N-glycosylation as expected 28 and did not affect the structure of SC, which retained its ability to cross-link to the ADD-ST vaccine platform in a dose dependent manner ( Figure   3c ). The proper folding of the glycosylated RBD exposed at the surface of the particles and its ability to bind ACE2 were assessed in a functional viral entry assay via competition with SARS-CoV-2 Spike pseudo-typed virions (Figure 4c) . A surface plasmon resonance (SPR) experiment confirmed the high affinity interaction of ADD-RBD to ACE2, the highly stable interaction observed suggesting an avidity effect of the multivalent particle exposing multiple copies of RBD (Figure 4a ).

The ability of the RBD-decorated ADDomer to elicit an anti-SARS-CoV-2 humoral response was then studied in mice. As expected, we confirmed that displaying the RBD in a multimerized manner led to a strong improvement in immunogenicity (groups 3 and 4 versus groups 1 and 2). Indeed, this was clearly apparent from the first injection where the groups with decorated particles showed a significant anti-RBD response at Day 13 as measured in ELISA (Figure 5c ), whereas no response was observed for the other groups. After the second immunization, although a response was observed in the non-decorated groups, the titers attained in the decorated groups were about 10 fold greater ( Figure 6a) . Notably, the anti-RBD response in the latter groups endured over time with similar titers at 2 and 4 weeks following the second immunization ( Figure 6b ). The anti-SARS-CoV-2 RBD sera were further assessed for their capacity to neutralize SARS-CoV-2 in pseudo-typed virus-based assay ( Figure 7) . As seen for binding responses, a neutralizing activity was observed in the RBD-decorated groups after the first immunization. Overall, a good correlation between ELISA and neutralizing titers was observed. Strong neutralizing titers were attained in all mice immunized with ADD-RBD after the boost immunization, showing the ability of our vaccine platform to elicit functional antibody responses with a potential protective activity. The low titers obtained in mice immunized with RBD and naked ADDomer (no decoration) again demonstrated that the high immunogenicity achieved with the decorated VLPs originated from the antigen multimeric display. The data are in adequacy with results obtained with similar vaccine platforms using multimeric display of the SARS-CoV-2 RBD on scaffolds such as the 24mer-ferritin, the 60mer dodecahedral thermophilic aldolase 24, 29, 30 . In contrast to these latter vaccine platforms, our particles originate from a human virus, Adenovirus serotype 3 (HAd3), which is known to have a relatively high seroprevalence 31, 32 . A potentially detrimental impact of preexisting immunity on the immunogenicity of adenovirus-based viral vectors has been described 33 , which thus led us to explore whether such effect may also be encountered with our adenovirus-derived VLP platform. Interestingly, in contrast to adenovirus-viral vectors, our adenovirus-inspired VLP platform appears to benefit from pre-immunity. Indeed, mice with immunity to ADDomer at the time of the first immunization were found to respond with greater antibody titers against RBD than naive mice (group 4 versus group 3, Figure 5c ). This beneficial effect may be in particular explained by the formation of immune complexes leading to a better antigen presentation increasing immunogenicity 34 . This property persisted after the second immunization although the differences between groups 3 and 4 were less marked, probably due to an anti-ADDomer response generated in group 3 during the first injection.

In conclusion, we designed a new adenovirus-inspired vaccine platform to achieve high immunogenicity against the displayed antigen. This platform efficacy is not dependent on the immunological status against adenovirus which allows to consider its use in a large coverage.

We exemplified in the present work the ability of this technology to generate SARS-CoV-2 potent neutralizing antibodies against the Wuhan strain, but its ease of use allows to envision a rapid application to different variants of concern (VOCs). Moreover, the versatility of the vaccine platform paved the way to generate mosaic particles displaying RBDs from different betacoronaviruses 35 or from different SARS-CoV-2 variants at once. More generally, this novel platform constitutes a precious tool in the preparedness to the probable emerging pathogens.

The baculovirus expression system was used for both the production of ADDomer-SpyTag (ADD-ST) and for the RBD fused to SpyCatcher (RBD-SC). Synthetic DNA (Genscript) was cloned in the pACEBac1 using the restriction sites BamHI and HindIII. For RBD-SC, the SARS-CoV-2 spike sequence (320-554) was cloned upstream of the Spy Catcher and a hexa

His-Tag was added in C-terminus of SC. This fusion protein was secreted using the melittin signal peptide present in the vector. Recombinant baculoviruses were made by transposition with an in house bacmid expressing Yellow Fluorescent Protein, as previously described 18 .

Baculovirus were amplified on Sf21 cells at low multiplicity of infection (MOI) and after two amplification cycles were used to infect insect cells for 64-72h at high MOI. For ADD-ST production, the infected cells were pelleted and recovered whereas for RBD-SC cells were discarded and the supernatant was saved.

The ADDomer and ADD-ST was purified according to classical protocol 36 Pre-immunized group received 2 weeks before the first dose of vaccine (day -15) the ADDomer vector alone (5µg in 100 µl final volume, in the right flank). The day before each vaccination, and 2 and 4 weeks after the last vaccination, 100µl of blood was withdrawn for serologic tests.

For retro-orbital blood sampling, mice were anesthetized with 4% Isoflurane.

Negative staining Regeneration of the surfaces was achieved by 10mM Glycine pH2. Binding curves were analyzed using BIAEvaluation software (GE Healthcare) and data was fit to a 1:1 Langmuir with drifting baseline interaction model.

Pseudovirus production and titration Neutralization assays were performed using lentiviral pseudotypes harbouring the SARS-CoV-2 spike and encoding luciferase. Briefly, gag/pol and luciferase plasmids were co-transfected with a SARS-CoV-2 spike plasmid with a C-term deletion of 18aa at 1/0 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structural basis of receptor recognition by SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Potently neutralizing and protective human antibodies against SARS-CoV-2

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Adenovirus dodecahedron, a new vector for human gene transfer

The Adenovirus Dodecahedron: Beyond the Platonic Story

Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display

Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

Structural Analysis and Optimization of the Covalent Association between SpyCatcher and a Peptide Tag

Power to the protein: enhancing and combining activities using the Spy toolbox

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

Neutralizing antiviral B cell responses

Sitespecific glycan analysis of the SARS-CoV-2 spike

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

Replication-Deficient Human Adenovirus Type 35

Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

Adenovirus receptors: implications for targeting of viral vectors

Humoral Responses Elicited by Adenovirus Displaying Epitopes Are Induced Independently of the Infection Process and Shaped by the Toll-Like Receptor/MyD88 Pathway

Feedback regulation by IgG antibodies

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Use of dodecahedron 'VLPs' as an alternative to the whole adenovirus

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No 682286). D.H is supported by GEFLUC Dauphiné-Savoie, Ligue contre le Cancer Comité Isère, Université Grenoble Alpes IDEX Initiatives de Recherche Stratégiques and Fondation du Souffle-Fonds de recherche en santé respiratoire (FdS-FRSR). We thank Aymeric Peuch for help with the usage of the EM computing cluster and Emmanuelle Neumann for the training of CC in negative staining and Leandro Estrozi for help with image analysis

Grenoble Instruct-ERIC centre (ISBG ; UAR 3518 CNRS-CEA-UGA-EMBL) within the

Grenoble Partnership for Structural Biology (PSB), supported by FRISBI

The electron microscope facility is supported by the Auvergne-Rhône-Alpes Region, the Fondation Recherche Medicale (FRM), the fonds FEDER and the GIS-Infrastructures en Biologie Sante et Agronomie (IBISA)

IBS acknowledges integration into the Interdisciplinary Research Institute of Grenoble (IRIG, CEA). V.D is an internship of Master de Biologie

Immunological characterization and virus neutralization was performed by A.A, I.B. and M.B With input from all authors, P.F and P.P wrote the manuscript